Condition: Non-metastatic Castration-resistant Prostate Cancer · Sponsor: Bayer
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors. In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant). Prostate-specific antigen (PSA) is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development. Men with nmCRPC usually have higher levels of (PSA) than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body. The study treatment darolutamide is already available in certain countries for doctors to prescribe to men with prostate cancer that has not yet spread to other parts of the body. It works by blocking androgens from attaching to proteins in cancer cells in the prostate. Results of a previous study in men with high-risk nmCRPC who received darolutamide in addition t…
This description comes directly from the study's public registry record.
Bayer Clinical Trials Contact · (+)1-888-84 22937 · clinical-trials-contact@bayer.com
Always discuss trial participation with your own doctor first.
| HCG-City Cancer Centre | Vijayawada, Andhra Pradesh, India | Terminated |
| King George Hospital | Visakhapatnam, Andhra Pradesh, India | Terminated |
| Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital) | Nadiād, Gujarat, India | Completed |
| Surat Institute of Digestive Sciences | Surat, Gujarat, India | Terminated |
| KLES Dr. Prabhakar Kore Hospital & Medical Research Centre | Belagavi, Karnataka, India | Withdrawn |
| HCG Oncology Center | Bengaluru, Karnataka, India | Completed |
| Fortis Hospital Bangalore | Bengaluru, Karnataka, India | Terminated |
| Amrita Institute of Medical Sciences | Kochi, Kerala, India | Recruiting |
| Regional Cancer Centre - Thiruvananthapuram | Thiruvananthapuram, Kerala, India | Recruiting |
| MVR Cancer Centre and Research Institute | Vellalasseri, Kerala, India | Recruiting |
| Sujan Surgical Cancer Hospital & Amravati Cancer Foundation | Amravati, Maharashtra, India | Completed |
| Tata Memorial Hospital | Mumbai, Maharashtra, India | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05348876